NASDAQ : AVTX
Avalo Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 399.01M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 384.53M |
| Enterprise Value | -15.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 53.63M |
| Shares Outstanding | 53.63M |
| Shares Change (YoY) | +158.89% |
| Shares Change (QoQ) | +116.85% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 111.10% |
| Float | 37.31M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6,517.41 |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 19.31 |
| Quick Ratio | 18.94 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -36.27% |
| Return on Assets (ROA) | -18.50% |
| Return on Invested Capital (ROIC) | -187.88% |
| Return on Capital Employed (ROCE) | -19.45% |
| Weighted Average Cost of Capital (WACC) | 8.07% |
| Revenue Per Employee | $1,788 |
| Profits Per Employee | -$3.04M |
| Employee Count | 33 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 170,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -60.25% |
| 50-Day Moving Average | 14.77 |
| 200-Day Moving Average | 16.03 |
| Relative Strength Index (RSI) | 22.62 |
| Average Volume (20 Days) | 2,804,323 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11.96M |
| Short Previous Month | 11.41M |
| Short % of Shares Out | 22.31% |
| Short % of Float | 32.07% |
| Short Ratio (days to cover) | 10.66 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 59,000 |
| Gross Profit | -47.89M |
| Operating Income | -91.36M |
| Pretax Income | -100.16M |
| Net Income | -100.33M |
| EBITDA | -91.25M |
| EBIT | -91.36M |
| Loss Per Share | -$4.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 400.28M |
| Total Debt | 242,000 |
| Net Cash | 400.03M |
| Net Cash Per Share | $7.46 |
| Equity (Book Value) | 448.66M |
| Book Value Per Share | 8.48 |
| Working Capital | 386.80M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -68.29M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 109,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -68.29M |
| FCF Per Share | -$1.27 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -154,847.46% |
| Pretax Margin | -169,767.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -158.89% |
| Shareholder Yield | -158.89% |
| Earnings Yield | -58.24% |
| FCF Yield | -17.76% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $36.60 |
| Price Target Difference | 410.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:240 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.67 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |